NCT00556374 2023-07-27
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Amgen
Phase 3 Completed
Clinical Trials
21 trialsNCT00321464 2022-11-08
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.
Amgen
Phase 3 Completed
NCT01345019 2022-11-08
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Amgen
Phase 3 Completed
NCT00330759 2022-11-07
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
Amgen
Phase 3 Completed
NCT01951586 2021-10-25
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Amgen
Phase 2 Completed
NCT00622505 2021-05-26
Z-MARK
Novartis
Phase 4 Completed
NCT00321620 2018-08-29
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer
Amgen
Phase 3 Completed
NCT00399802 2018-08-16
A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01920568 2017-01-16
A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors
GlaxoSmithKline
Phase 3 Completed
NCT02739594 2016-07-22
COMPARE
Hoffmann-La Roche
Phase 3 Terminated
NCT00375505 2015-09-07
The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss
Novartis
Phase 3 Completed
NCT00172042 2015-05-04
A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
Novartis
Phase 3 Completed
NCT00333229 2014-11-25
A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss
Novartis
Phase 4 Terminated
NCT00320710 2014-08-22
Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer
Novartis
Phase 3 Completed
NCT00242567 2014-05-07
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer
Novartis
Phase 3 Completed
NCT00171340 2012-04-16
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
Novartis
Phase 3 Completed
NCT00171314 2012-04-11
The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer
Novartis
Phase 3 Completed
NCT00171925 2012-04-11
Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I
Novartis
Phase 3 Terminated
NCT00375427 2012-04-11
Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions
Novartis
Phase 3 Completed
NCT00332709 2011-11-16
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
Novartis
Phase 3 Completed
NCT00104104 2011-06-29
A Multiple Myeloma Trial in Patients With Bone Metastases
Novartis
Phase 4 Completed